SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : T/FIF, a New Plateau
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (422)4/11/2001 2:00:54 PM
From: tuck   of 2243
 
Rick,

Angiomax is a modified form of Hirulog that did better in trials, showing comparable efficacy to Heparin, but noticeably better safety and bleeding reduction. It is likely to be more expensive, though the company is working on second generation production technology (impact on cost unclear, but presumably positive) I've been digging, and a couple of abstracts and excerpts from the recent 10-K are up:

Message 15648307

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News